These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 26882065)

  • 1. Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
    Harrington BS; He Y; Davies CM; Wallace SJ; Adams MN; Beaven EA; Roche DK; Kennedy C; Chetty NP; Crandon AJ; Flatley C; Oliveira NB; Shannon CM; deFazio A; Tinker AV; Gilks CB; Gabrielli B; Brennan DJ; Coward JI; Armes JE; Perrin LC; Hooper JD
    Br J Cancer; 2016 Feb; 114(4):417-26. PubMed ID: 26882065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.
    He Y; Wu AC; Harrington BS; Davies CM; Wallace SJ; Adams MN; Palmer JS; Roche DK; Hollier BG; Westbrook TF; Hamidi H; Konecny GE; Winterhoff B; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Tinker AV; Gilks CB; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD
    Oncogene; 2016 Jan; 35(4):468-78. PubMed ID: 25893298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation.
    Miyazawa Y; Uekita T; Hiraoka N; Fujii S; Kosuge T; Kanai Y; Nojima Y; Sakai R
    Cancer Res; 2010 Jun; 70(12):5136-46. PubMed ID: 20501830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of inside-out β1-integrin activation by CDCP1.
    Pollan SG; Huang F; Sperger JM; Lang JM; Morrissey C; Cress AE; Chu CY; Bhowmick NA; You S; Freeman MR; Spassov DS; Moasser MM; Carter WG; Satapathy SR; Shah K; Knudsen BS
    Oncogene; 2018 May; 37(21):2817-2836. PubMed ID: 29511352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration.
    Dong Y; He Y; de Boer L; Stack MS; Lumley JW; Clements JA; Hooper JD
    J Biol Chem; 2012 Mar; 287(13):9792-9803. PubMed ID: 22315226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer.
    Harrington BS; He Y; Khan T; Puttick S; Conroy PJ; Kryza T; Cuda T; Sokolowski KA; Tse BW; Robbins KK; Arachchige BJ; Stehbens SJ; Pollock PM; Reed S; Weroha SJ; Haluska P; Salomon C; Lourie R; Perrin LC; Law RHP; Whisstock JC; Hooper JD
    Theranostics; 2020; 10(5):2095-2114. PubMed ID: 32104500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADAM9 enhances CDCP1 protein expression by suppressing miR-218 for lung tumor metastasis.
    Chiu KL; Kuo TT; Kuok QY; Lin YS; Hua CH; Lin CY; Su PY; Lai LC; Sher YP
    Sci Rep; 2015 Nov; 5():16426. PubMed ID: 26553452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of autophagy by CUB domain-containing protein 1 signaling is essential for anchorage-independent survival of lung cancer cells.
    Uekita T; Fujii S; Miyazawa Y; Hashiguchi A; Abe H; Sakamoto M; Sakai R
    Cancer Sci; 2013 Jul; 104(7):865-70. PubMed ID: 23510015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis.
    Liu H; Ong SE; Badu-Nkansah K; Schindler J; White FM; Hynes RO
    Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1379-84. PubMed ID: 21220330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIF-2α regulates CDCP1 to promote PKCδ-mediated migration in hepatocellular carcinoma.
    Cao M; Gao J; Zhou H; Huang J; You A; Guo Z; Fang F; Zhang W; Song T; Zhang T
    Tumour Biol; 2016 Feb; 37(2):1651-62. PubMed ID: 26307391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CUB-domain-containing protein 1 overexpression in solid cancers promotes cancer cell growth by activating Src family kinases.
    Leroy C; Shen Q; Strande V; Meyer R; McLaughlin ME; Lezan E; Bentires-Alj M; Voshol H; Bonenfant D; Alex Gaither L
    Oncogene; 2015 Oct; 34(44):5593-8. PubMed ID: 25728678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients.
    Emerling BM; Benes CH; Poulogiannis G; Bell EL; Courtney K; Liu H; Choo-Wing R; Bellinger G; Tsukazawa KS; Brown V; Signoretti S; Soltoff SP; Cantley LC
    Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3483-8. PubMed ID: 23378636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling.
    Sandercock AM; Rust S; Guillard S; Sachsenmeier KF; Holoweckyj N; Hay C; Flynn M; Huang Q; Yan K; Herpers B; Price LS; Soden J; Freeth J; Jermutus L; Hollingsworth R; Minter R
    Mol Cancer; 2015 Jul; 14():147. PubMed ID: 26227951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Significance of CDCP1 Expression in Colorectal Cancer and Effect of Its Inhibition on Invasion and Migration.
    Chou CT; Li YJ; Chang CC; Yang CN; Li PS; Jeng YM; Chen ST; Kuo ML; Lin IC; Lin BR
    Ann Surg Oncol; 2015 Dec; 22(13):4335-43. PubMed ID: 25820997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis.
    Chiu KL; Lin YS; Kuo TT; Lo CC; Huang YK; Chang HF; Chuang EY; Lin CC; Cheng WC; Liu YN; Lai LC; Sher YP
    Oncotarget; 2017 Jul; 8(29):47365-47378. PubMed ID: 28537886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface.
    Adams MN; Harrington BS; He Y; Davies CM; Wallace SJ; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD
    Oncogene; 2015 Mar; 34(11):1375-83. PubMed ID: 24681947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation.
    Wright HJ; Hou J; Xu B; Cortez M; Potma EO; Tromberg BJ; Razorenova OV
    Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6556-E6565. PubMed ID: 28739932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stratum basale keratinocyte expression of the cell-surface glycoprotein CDCP1 during epidermogenesis and its role in keratinocyte migration.
    McGovern JA; Heinemann JR; Burke LJ; Dawson R; Parker TJ; Upton Z; Hooper JD; Manton KJ
    Br J Dermatol; 2013 Mar; 168(3):496-503. PubMed ID: 23121233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration.
    Seidel J; Kunc K; Possinger K; Jehn C; Lüftner D
    Biochem Biophys Res Commun; 2011 Oct; 414(1):226-32. PubMed ID: 21945930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells.
    Faddaoui A; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Gobeil S; Morin C; Macdonald E; Vanderhyden B; Bachvarov D
    Oncotarget; 2016 Mar; 7(12):14125-42. PubMed ID: 26871602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.